allocetra-ots

Cell therapyexperimental

Clinical trial activity

13 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
10
Phase 2
7
Phase 3
0
Phase 4
0

Earliest trial started Jan 27, 2019 (NCT03925857)

Timeline

2010s

  1. Jan 1, 2019

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetTissue restoration

    tissue restoration

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06748651Phase 1Dec 15, 2024Tel Aviv University
NCT06522035Phase 1Aug 31, 2024Enlivex Therapeutics Ltd.
NCT06459063Phase 1/Phase 2 (Phase 2)Jun 10, 2024Hebrew University
NCT06233474Phase 1/Phase 2 (Phase 2)Jan 26, 2024Enlivex Therapeutics Ltd., Nordic Bioscience
NCT06208241Early Phase 1 (Phase 1)Jul 12, 2023Enlivex Therapeutics Ltd., Hebrew University
NCT05581719Phase 1/Phase 2 (Phase 2)Oct 31, 2022Enlivex Therapeutics Ltd., Tel Aviv University
NCT05431907Phase 1/Phase 2 (Phase 2)Jun 29, 2022Enlivex Therapeutics Ltd., Sheba Medical Center
NCT04922957Phase 2Sep 30, 2021Enlivex Therapeutics Ltd.
NCT04659304Phase 1Mar 31, 2021Enlivex Therapeutics Ltd.
NCT04612413Phase 2Nov 15, 2020Cato Research, Clalit Health Services, Enlivex Therapeutics Ltd.
NCT04590053Phase 2Oct 20, 2020Barzilai Medical Center, Hebrew University, Tel Aviv University
NCT04513470Phase 1Aug 1, 2020Hebrew University
NCT03925857Phase 1Jan 27, 2019Enlivex Therapeutics Ltd.
Showing 13 of 13 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Enlivex Therapeutics Ltd.For profit9822019
Hebrew UniversityAcademic/Hospital4422020
Tel Aviv UniversityAcademic/Hospital3122020
Barzilai Medical CenterAcademic/Hospital1012020
Cato ResearchFor profit1012020
Clalit Health ServicesAcademic/Hospital1012020
Nordic BioscienceFor profit1012024
Sheba Medical CenterAcademic/Hospital1012022
8 organizations
Page 1 / 1